Initial phase III results of the first trial in newly diagnosed multiple myeloma

Share :
Published: 10 Dec 2013
Views: 3167
Rating:
Save
Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, France

During the 2013 ASH Annual Meeting, Dr Thierry Facon presents data on the First (Frontline Investigation of Revlimid Dexamethasone Versus Standard Thalidomide) Trial.

This Phase III trial was designed to compare the efficacy and safety of a combination of two oral drugs, lenalidomide and low-dose dexamethasone (Rd), to a standard combination therapy including melphalan, prednisone, and thalidomide (MPT) used worldwide to treat patients with newly diagnosed multiple myeloma (NDMM).

A total of 1,623 NDMM patients ineligible for stem cell transplant due to age or other factors were randomised into three treatment arms: continuous Rd until disease progression, Rd for 72 weeks, or MPT for 72 weeks. After a median follow-up period of 37 months, the study met its primary endpoint by demonstrating that those patients treated with continuous Rd were more than a quarter (28%) less likely to experience disease progression or death than those patients treated with MPT.

Further, patients in both Rd treatment arms showed improvements in overall survival, overall response rate, and duration of response. While the safety profiles of the two treatment regimens were similar, patients treated with Rd showed fewer secondary hematologic malignancies than those treated with MPT.